title: IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.
abstract: Antiestrogens are effective therapies for the management of many estrogen receptor-alpha (ER)-positive breast cancers. Nonetheless, both de novo and acquired resistance occur and remain major problems in the clinical setting. IFNgamma is an inflammatory cytokine that induces the expression and function of IFN regulatory factor 1 (IRF1), a tumor suppressor gene that can increase antiestrogen responsiveness. We show that IFNgamma, but not IFNalpha, IFNbeta, or fulvestrant (ICI; ICI 182,780; Faslodex), induces IRF1 expression in antiestrogen-resistant MCF7/LCC9 and LY2 cells. Moreover, IFNgamma restores the responsiveness of these cells to fulvestrant. Increased IRF1 activation suppresses NF-kappaB p65 (RELA) activity, inhibits the expression of prosurvival (BCL2, BCL-W), and induces the expression of proapoptotic members (BAK, mitochondrial BAX) of the BCL2 family. This molecular signaling is associated with the activation of signal transducer and activator of transcription 1 and leads to increased mitochondrial membrane permeability; activation of caspase-7 (CASP7), CASP8, and CASP9; and induction of apoptosis but not autophagy. Whereas antiestrogen-resistant cells are capable of inducing autophagy through IFN-mediated signaling, their ability to do so through antiestrogen-regulated signaling is lost. The abilities of IFNgamma to activate CASP8, induce apoptosis, and restore antiestrogen sensitivity are prevented by siRNA targeting IRF1, whereas transient overexpression of IRF1 mimics the effects of IFNgamma treatment. These observations support the exploration of clinical trials combining antiestrogens and compounds that can induce IRF1, such as IFNgamma, for the treatment of some ER-positive breast cancers.
authors.affiliation: Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC 20057, USA.
authors.forename: Yanxia
authors.initials: Y
authors.lastname: Ning
authors.forename: Rebecca B
authors.initials: RB
authors.lastname: Riggins
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Mulla
authors.forename: Haniee
authors.initials: H
authors.lastname: Chung
authors.forename: Alan
authors.initials: A
authors.lastname: Zwart
authors.forename: Robert
authors.initials: R
authors.lastname: Clarke
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D020169:Caspases / Q000378:metabolism / Q000502:physiology; D004353:Drug Evaluation, Preclinical; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000235:genetics*; D004357:Drug Synergism; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D050856:Interferon Regulatory Factor-1 / Q000235:genetics / Q000378:metabolism; D007371:Interferon-gamma / Q000494:pharmacology*; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D050794:STAT1 Transcription Factor / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; C494257:IRF1 protein, human; D050856:Interferon Regulatory Factor-1; D016328:NF-kappa B; D019253:Proto-Oncogene Proteins c-bcl-2; D050794:STAT1 Transcription Factor; C494079:STAT1 protein, human; D000077267:Fulvestrant; D004958:Estradiol; D007371:Interferon-gamma; D020169:Caspases
references.citation: Br J Cancer. 2000 Nov;83(10):1380-6
references.pmid: 11044365
references.citation: Cancer Res. 2004 Jun 1;64(11):4030-9
references.pmid: 15173018
references.citation: Br J Cancer. 1987 Mar;55(3):255-7
references.pmid: 3567059
references.citation: Cancer. 1987 Nov 15;60(10):2419-23
references.pmid: 3664427
references.citation: Mol Cancer Ther. 2005 Jan;4(1):33-41
references.pmid: 15657351
references.citation: Carcinogenesis. 2005 Sep;26(9):1527-35
references.pmid: 15878912
references.citation: Mol Cell Biol. 2003 Oct;23(19):6887-900
references.pmid: 12972607
references.citation: Science. 1994 Jun 3;264(5164):1415-21
references.pmid: 8197455
references.citation: Mol Cell Biol. 1996 Oct;16(10):5546-56
references.pmid: 8816467
references.citation: Vitam Horm. 2005;71:201-37
references.pmid: 16112269
references.citation: FASEB J. 2010 Jun;24(6):2040-55
references.pmid: 20154269
references.citation: Oncogene. 2003 Oct 20;22(47):7316-39
references.pmid: 14576841
references.citation: Oncogene. 2004 Feb 5;23(5):1125-35
references.pmid: 14762441
references.citation: Endocrinology. 1985 Oct;117(4):1409-17
references.pmid: 4029083
references.citation: Nature. 1995 Aug 17;376(6541):596-9
references.pmid: 7637809
references.citation: Proc Natl Acad Sci U S A. 1992 May 1;89(9):4037-41
references.pmid: 1570330
references.citation: Pharmacol Rev. 2001 Mar;53(1):25-71
references.pmid: 11171938
references.citation: J Endocrinol. 1989 Jul;122(1):331-40
references.pmid: 2769157
references.citation: Annu Rev Biochem. 1987;56:727-77
references.pmid: 2441659
references.citation: Breast Cancer Res Treat. 2001 Jul;68(2):127-38
references.pmid: 11688516
references.citation: Cancer. 2003 Jul 15;98(2):229-38
references.pmid: 12872340
references.citation: Cancer Res. 1997 Aug 15;57(16):3486-93
references.pmid: 9270017
references.citation: Breast Cancer Res Treat. 1994;32(1):39-47
references.pmid: 7819584
references.citation: Biochem Biophys Res Commun. 2000 Mar 5;269(1):31-4
references.pmid: 10694472
references.citation: Int J Oncol. 2006 Jan;28(1):67-76
references.pmid: 16327981
references.citation: Bioinformatics. 2005 Jul 1;21(13):2933-42
references.pmid: 15860560
references.citation: Lancet. 1995 Jan 7;345(8941):29-30
references.pmid: 7799704
references.citation: J Biol Chem. 1996 Mar 8;271(10):5790-4
references.pmid: 8621447
references.citation: Oncogene. 2000 Jul 13;19(30):3372-83
references.pmid: 10918594
references.citation: Oncogene. 2004 Nov 18;23(54):8743-55
references.pmid: 15467738
references.citation: J Clin Invest. 2001 Feb;107(3):241-6
references.pmid: 11160144
references.citation: PLoS One. 2010 Jan 06;5(1):e8604
references.pmid: 20062536
references.citation: J Immunol. 2000 Apr 1;164(7):3512-8
references.pmid: 10725705
references.citation: Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59
references.pmid: 18097445
references.citation: EMBO J. 1997 Jan 15;16(2):406-16
references.pmid: 9029159
references.citation: EMBO J. 1998 Jul 1;17(13):3660-8
references.pmid: 9649436
references.citation: Proc Natl Acad Sci U S A. 1990 Sep;87(17):6883-7
references.pmid: 2395882
references.citation: Lancet. 1992 Jan 4;339(8784):1-15
references.pmid: 1345950
references.citation: Mol Cell Biol. 1997 Jul;17(7):3629-39
references.pmid: 9199297
references.citation: Int J Cancer. 2003 Jul 10;105(5):607-12
references.pmid: 12740907
references.citation: J Interferon Cytokine Res. 2005 Oct;25(10):587-94
references.pmid: 16241857
references.citation: Br J Cancer. 2004 Mar;90 Suppl 1:S11-4
references.pmid: 15094759
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Nucleic Acids Res. 1997 Nov 1;25(21):4346-54
references.pmid: 9336467
references.citation: J Biol Chem. 2000 Mar 3;275(9):6499-508
references.pmid: 10692454
references.citation: Oncogene. 2007 Sep 27;26(44):6420-30
references.pmid: 17452973
references.citation: Cancer Res. 2004 Nov 15;64(22):8381-8
references.pmid: 15548708
references.citation: Cancer Res. 1989 May 15;49(10):2698-702
references.pmid: 2469536
references.citation: Nature. 1996 Aug 29;382(6594):816-8
references.pmid: 8752276
references.citation: Cancer Res. 2002 Jun 15;62(12):3428-37
references.pmid: 12067985
references.citation: Cell. 1994 Jun 17;77(6):829-39
references.pmid: 8004672
references.citation: J Steroid Biochem. 1988 Oct;31(4B):645-53
references.pmid: 3199810
references.citation: Cancer Res. 1993 Jan 15;53(2):283-90
references.pmid: 8380254
references.citation: Biochem Biophys Res Commun. 2006 Apr 21;342(4):1249-56
references.pmid: 16516145